Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Transition from hormone-sensitive to castration-resistant prostate cancer

First-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC)

Date

03 Dec 2023

Session

Transition from hormone-sensitive to castration-resistant prostate cancer

Topics

Tumour Site

Prostate Cancer

Presenters

Deborah Mukherji

Authors

D. Mukherji

Author affiliations

  • Medical Oncology, Clemenceau Medical Center, 41701 - Dubai/AE

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.